Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI

Previous studies have identified high on treatment platelet reactivity (HTPR) as a potent factor predicting ischemic events for patients with coronary heart disease. We assessed the efficacy and safety of ticagrelor (90 mg twice-daily) and double-dose of clopidogrel (150 mg once-daily) among Chinese...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International Heart Journal 2017, Vol.58(2), pp.167-173
Hauptverfasser:	Wu, Xi, Liu, Gang, Lu, Jie, Zheng, Xin-Xin, Cui, Jin-Gang, Zhao, Xue-Yan, Huang, Xiao-Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine - administration & dosage Adenosine - analogs & derivatives Aged Cardiovascular disease Circulatory system Clopidogrel Coronary artery disease CYP2C19 Cytochrome P-450 CYP2C19 - genetics Female Genetic diversity Heart diseases High platelet reactivity Humans Ischemia Male Middle Aged Patients Percutaneous Coronary Intervention - adverse effects Platelet Activation - genetics Platelets Postoperative Complications - prevention & control Purinergic P2Y Receptor Antagonists - administration & dosage Statins Thrombosis - etiology Thrombosis - prevention & control Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!